Abstract |
Based on a clinical differential effect of the action of a new hypoxic cell radiosensitizer, AK-2123 (a 3-nitro-1,2,4-triazole), on locally advanced cervix cancer (Stage II-B and III-B), a Phase I/II clinical trial has been carried out on 80 consecutive patients. They were intratumorally injected with AK-2123, wt 1% and 2%, 30 min before the delivery of external radiation therapy. The short-term effects show that exophytic types of lesions respond far better than endophytic types and AK-2123 may be replacing intracavitary radium for exophytic Stage II-B cervix cancer as the standard therapy for this neoplasm in our patients. Treatment is well tolerated and no neurological toxicity has been noted.
|
Authors | A H García-Angulo, V T Kagiya |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 22
Issue 3
Pg. 589-91
( 1992)
ISSN: 0360-3016 [Print] United States |
PMID | 1735697
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Radiation-Sensitizing Agents
- Triazoles
- AK 2123
|
Topics |
- Carcinoma, Squamous Cell
(drug therapy, radiotherapy)
- Combined Modality Therapy
- Drug Evaluation
- Female
- Humans
- Radiation-Sensitizing Agents
(administration & dosage, therapeutic use)
- Triazoles
(administration & dosage, therapeutic use)
- Uterine Cervical Neoplasms
(drug therapy, radiotherapy)
|